GlassScriptPhysician profile
Lawrence Gervasi
NPI 1265400592
$1,052,158.24
in general payments reported to CMS, 2019-2025
66 companies · $146K in 2025
The $146K reported for 2025 was more than what 99% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198K · 2020: $91K · 2021: $105K · 2022: $182K · 2023: $178K · 2024: $152K · 2025: $146K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $366K · Travel and Lodging: $70K · Consulting Fee: $28K · Food and Beverage: $12K · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $366,420.94 |
| Travel and Lodging | $69,738.38 |
| Consulting Fee | $27,856.71 |
| Food and Beverage | $11,502.51 |
| Education | $227.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $422,400.56 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $218,738.88 | 2019-2025 | |
| Janssen Biotech, INC. | $206,039.98 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Sumitomo Pharma America, INC. | $62,178.71 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $55,682.57 | 2019-2025 | Provenge |
| Myovant Sciences INC. | $28,775.82 | 2021-2022 | |
| Pfizer INC. | $19,077.78 | 2019-2024 | |
| Astellas Pharma Global Development | $7,772.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $5,638.57 | 2024-2025 | |
| Amgen INC. | $4,595.23 | 2019-2023 | Xgeva |
| Avyxa Pharma, LLC | $3,526.99 | 2025 | |
| Clovis Oncology, INC. | $3,254.09 | 2019-2021 | |
| Exelixis INC. | $1,980.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $1,976.10 | 2020-2022 | |
| Genzyme Corporation | $1,834.16 | 2019-2021 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,356.67 | 2020-2025 | Lynparza, Imfinzi |
| Janssen Pharmaceuticals, INC | $1,329.79 | 2019-2025 | |
| Blue Earth Diagnostics | $909.88 | 2019-2025 | Posluma |
| Tolmar Pharmaceuticals, INC. | $718.55 | 2020-2022 | |
| Tolmar, INC. | $666.40 | 2023-2025 | Eligard, Jatenzo, Rubraca |
| Urogen Pharma, INC. | $383.90 | 2021-2025 | |
| Progenics Pharmaceuticals, INC. | $336.43 | 2021-2025 | Pylarify |
| Abbvie INC. | $298.20 | 2019-2025 | |
| Antares Pharma, INC. | $173.48 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Verity Pharmaceuticals INC. | $169.28 | 2022-2025 | Trelstar |
| Allergan, INC. | $156.75 | 2019-2022 | |
| Immunitybio, INC. | $155.85 | 2024-2025 | |
| Teleflex LLC | $143.06 | 2021-2025 | Urolift |
| C. R. Bard, INC. & Subsidiaries | $135.75 | 2023 | Bard Urinary Drainage Bag |
| Tempus Ai, INC | $134.71 | 2024-2025 | Xt Cdx |
| Procept Biorobotics Corporation | $121.75 | 2023 | Aquabeam Robotic System |
| Convatec INC. | $109.92 | 2021-2024 | |
| Axonics, INC. | $103.23 | 2023-2024 | Bulkamid, Axonics |
| Sun Pharmaceutical Industries INC. | $103.23 | 2020-2023 | Yonsa |
| Urovant Sciences INC | $102.06 | 2022 | |
| Merck Sharp & Dohme LLC | $100.28 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Coloplast Corp | $97.38 | 2019-2022 | |
| Rochester Medical Corporation | $94.07 | 2021-2022 | |
| Medtronic USA, INC. | $84.15 | 2019-2020 | |
| Telix Pharmaceuticals | $66.04 | 2023-2025 | Illuccix |
| Accord Healthcare, INC. | $63.55 | 2022-2023 | |
| Abc Home Medical Supply, INC. | $63.10 | 2024 | |
| Laborie Medical Technologies Corp. | $59.73 | 2024-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Boston Scientific Corporation | $56.83 | 2024 | Ams 700, Rezum Generator |
| Ferring Pharmaceuticals INC. | $54.74 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $38.50 | 2020 | |
| Pharmaand Gmbh | $37.69 | 2025 | Rubraca |
| Clarus Therapeutics INC. | $31.37 | 2021 | |
| Calyxo, INC. | $29.47 | 2024-2025 | Cvac Aspiration System |
| Foundation Medicine, INC. | $26.81 | 2023 | |
| Dentsply Ih INC. | $24.99 | 2020-2021 | |
| Medtronic, INC. | $19.66 | 2024 | Interstim |
| Myriad Genetic Laboratories, INC. | $19.07 | 2024 | Prolaris |
| Endo USA, INC. | $17.00 | 2025 | Xiaflex |
| Dentsply Ih Ab | $16.08 | 2023 | Lofric |
| Koelis INC. | $14.76 | 2023 | |
| Olympus America INC. | $13.42 | 2024 | Itind System |
| Photocure INC | $13.16 | 2023 | Cysview |
| Metuchen Pharmaceuticals | $12.68 | 2019 | |
| Endo Pharmaceuticals INC. | $11.82 | 2019 | |
| Zyla Life Sciences, INC. | $11.04 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gervasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.